GLP-1 medications have taken center stage in the weight-loss arena this year, though certain elderly individuals are apparently opting out of the trend.
A research piece in JAMA from January 2025, examining over 125,000 individuals who were overweight or obese, indicated that almost 47% of participants with type 2 diabetes and 65% without diabetes ceased using their prescribed GLP-1s within twelve months of initiation.
Dr. John Batsis, an expert in geriatrics and obesity at the University of North Carolina School of Medicine, shared with The New York Times that adults over 65 represent "ideal candidates" for this treatment, given that obesity affects roughly 40% of seniors.
Understanding GLP-1 Drugs
These pharmaceuticals replicate a bodily gut hormone known as GLP-1 (glucagon-like peptide-1) and are mainly employed for managing type 2 diabetes and body weight. In addition, they have undergone trials for addressing other ailments, including sleep apnea and heart-related incidents.
Initiating and halting these medications frequently results in regained weight, heightened hunger, and forfeiture of related health perks, such as decreased blood pressure and cholesterol levels, as noted by Stamford Health and specialists. Moreover, the likelihood of obesity-linked issues, like heart conditions and sleep apnea, could rise.
Nevertheless, several elderly Americans are reportedly forsaking their weight-loss prescriptions due to various motives, ranging from pronounced adverse reactions to escalating expenses.
Outlined below are the four primary factors prompting seniors to abandon their GLP-1 regimens.
Reason 1: Elevated Expenses
The expense of GLP-1 treatments plays a pivotal role in sustaining therapy, particularly amid supply challenges.
The New York Times recounted the experience of 75-year-old Mary Bucklew, a former public transit worker residing in Delaware, who initially paid only a $25 monthly co-payment via her health plan for Ozempic to shed pounds.
She shed 25 pounds over six months and noted boosted vitality. Yet, her insurer informed her of discontinuing coverage, even after her pleas regarding its health necessity.
Without insurance support, the prescription would exceed $1,000 monthly out-of-pocket, compelling her to halt usage.
Certain GLP-1 producers have attempted to enhance affordability. In December 2025, Lilly declared plans to reduce the cost of Zepbound (tirzepatide) single-dose vials.
"An excessive number of individuals requiring obesity therapies encounter financial and coverage obstacles," stated Ilya Yuffa, executive vice president and president for Lilly USA, in the release. "This step highlights Lilly's dedication to enhancing availability in obesity care. We remain committed to offering additional alternatives, such as varied delivery methods and novel access routes, enabling more people to obtain essential medications."
Reason 2: Intense Adverse Reactions
In a discussion with Fox News Digital, Dr. Sue Decotiis, a physician specializing in medical weight reduction in New York City, affirmed that over half of elderly patients discontinue GLP-1 drugs because of expenses or side effects.
Typical reactions encompass nausea, vomiting, diarrhea, constipation, bloating, headaches, tiredness, and hair loss, per specialists.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
"Senior patients might experience heightened sensitivity to gastrointestinal issues," Decotiis explained. "Consistent oversight from a knowledgeable medical weight loss physician is essential."
Elderly individuals often begin dehydrated and may not intake sufficient water to counteract GLP-1 effects, Decotiis added.
"A scale measuring body composition can assess water, muscle, and bone content, visually demonstrating necessary actions," she suggested.
Novo Nordisk's official Wegovy guidelines caution that symptoms like nausea, vomiting, and diarrhea can cause dehydration, urging "adequate fluid intake to avert dehydration," particularly for those with renal problems.
Reason 3: Muscle Reduction
Muscle depletion, an additional downside of GLP-1 drugs, poses significant risks in this demographic, Decotiis warned.
When dehydrated or low on protein, individuals might shed more muscle than fat, she noted.
An October 2024 analysis from the American Heart Association referenced recent research indicating that fewer than half of pounds dropped via GLP-1s originated from fat, with a notable share from muscle tissue.
Muscle decline in seniors heightens fall and fracture dangers. Post-35, muscle mass can diminish by up to 2% annually, accelerating to 3% after 60, according to Harvard Health.
Reason 4: Insufficient Personalized Oversight
Experts concur that individuals can mitigate semaglutide-induced muscle loss risks through specific measures.
"It begins with increased vigilance from both the patient and doctor," Florida-based neurosurgeon and longevity specialist Dr. Brett Osborn told Fox News Digital previously. He advocates for routine physical assessments by physicians, adjusting doses if targets are unmet.
Medical professionals prescribing these drugs without "meticulous follow-up" may lead to treatment breakdowns, Decotiis stated.
"Implementing a bespoke dosing strategy aids in evading excessive reactions and promotes greater fat reduction, which is how GLP medications function over time and holistically," she informed Fox News Digital. "For select individuals, premium compounded GLP-1 enables precise dosing."
"Numerous patients halting GLP-1 therapies might have continued with appropriate tailored support."
Health tracking apps like Shotlee can assist in overseeing weight changes and potential side effects during such treatments.
